Fujifilm Kyowa Kirin Biologics
Ohtemachi Building 9F, 1-6-1 Ohtemachi
About Fujifilm Kyowa Kirin BiologicsFujifilm Kyowa Kirin Biologics creates revolutionary production processes and reduces the production cost of biosimilars by merging the technologies in advanced production, quality control and analysis which Fujifilm has developed over many years through its photographic film business, with the proprietary technologies and know-how accumulated by Kyowa Hakko Kirin through its biopharmaceutical R&D and manufacture.
CEO: Hideaki Nomura
Please click here for clinical trial information.
8 articles about Fujifilm Kyowa Kirin Biologics
Shares of Reata Pharmaceuticals have plunged nearly 40% in premarket trading after an FDA advisory panel recommended against the approval of its Alport syndrome disease treatment, bardoxolone.
A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan
Terumo Corporation announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd..
Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the U.S. Food and Drug Administration has approved Hulio®, a biosimilar to AbbVie's Humira®, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations.
Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab
Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for Hulio® (Product Code: FKB327), a biosimilar to AbbVie's Humira® (adalimumab), for all indications.
Mylan and Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion for Hulio™, Biosimilar Adalimumab
Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the Marketing Authorization Application of HulioTM (Product Code: FKB327), the companies' biosimilar to Humira® (adalimumab), for all indications.
Mylan Rumored to be in Discussions to Buy Merck KGaA’s Consumer Health Business, but Mylan Denies It
4/13/2018Mylan is reportedly in top-level talks with Germany’s Merck KGaA to buy its consumer health business. However, Mylan has denied it.
Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab)
Mylan acquires exclusive license to commercialize in Europe
Fujifilm Kyowa Kirin Biologics Announces Marketing Authorisation Application For FKB327 Accepted For Review By EMA